Scarica l'app Stockscreener
0.431
4.92%
0.0202
Dopo l'orario di chiusura:
.42
-0.011
-2.55%
Precedente Chiudi:
$0.4108
Aprire:
$0.41
Volume 24 ore:
31,869
Relative Volume:
0.05
Capitalizzazione di mercato:
$2.06M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+8.45%
1M Prestazione:
+13.96%
6M Prestazione:
+7.48%
1 anno Prestazione:
-84.88%
Intervallo 1D:
$0.40
$0.431
Intervallo di 1 settimana:
$0.38
$0.5359
Portata 52W:
$0.185
$2.99
Entero Therapeutics Inc Stock (ENTO) Company Profile
Nome
Entero Therapeutics Inc
Settore
Industria
Telefono
561-589-7020
Indirizzo
777 YAMATO ROAD, BOCA RATON
Confronta ENTO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.431 | 1.89M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Entero Therapeutics Inc Borsa (ENTO) Ultime notizie
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Entero Therapeutics names Richard Paolone interim CEO - MSN
Entero Therapeutics, Inc. SEC 10-Q Report - TradingView
Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement - marketscreener.com
Entero Therapeutics Finalizes Settlement with Mattress Liquidators - TipRanks
Entero (ENTO) Announces Public Offering of 16.67 Million Shares - GuruFocus
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
Layoff Tracker: Shape, Vor Cut Workforces - BioSpace
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Entero Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Entero Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Titan Environmental Solutions Inc. Appoints Edward J. Borkowski and Edward F. Feighan to its Board of Directors - The Manila Times
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Entero Therapeutics Delays 10-K Filing - TipRanks
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com
Entero Therapeutics Inc. (ENTO) reports earnings - Quartz
Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN
Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance
Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail
Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail
Hogs Close with Weakness on Thursday - The Globe and Mail
With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail
This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail
Celiac Disease Market Expected to Experience Major Growth - openPR
Significant Contract News Sends Energy Services Company Higher - The Globe and Mail
How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail
Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail
Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag
3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail
Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive
Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail
Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia
Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz
Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire
3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail
Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail
Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail
Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail
Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail
Entero Therapeutics Inc Azioni (ENTO) Dati Finanziari
Non sono disponibili dati finanziari per Entero Therapeutics Inc (ENTO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.33%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):